BlueRock Fully Enrolls Cell-based Trial for Advanced Parkinson’s
BlueRock Therapeutics has completed full enrollment in its open-label Phase 1 study evaluating the safety and preliminary efficacy of…
Articles by Steve Bryson, PhD
£2.68M Award to NRG Therapeutics Supports Work Into Potential DMT
NRG Therapeutics has received a £2.68M (about $3.4 million) award to support preclinical work into small molecule disease-modifying therapies for…
Brain Cell Transplant Shows Promise, Raises Questions in Mouse Study
Transplanting human nerve cells into the brains of mice in a model of Parkinson’s disease to replace dopamine-producing cells…
High-dose Cranberry Juice Shows Potential to Protect Brain Cells
Concentrated cranberry juice eased signs associated with Parkinson’s disease in a chemically induced rat model, but its long-term use…
Sense of Smell, While Poorer, May Help Patients in Enjoying Meals
People with Parkinson’s disease recognized food odors in a test called Sniffin’ Sticks better than they recognize the smell…
No Causal Link Between IBD, Parkinson’s in Large-scale Analysis
No causal relationship was identified between Parkinson’s disease and inflammatory bowel disease (IBD) or its major subtypes, Crohn’s…
Hand Movement Triggers Eyeblinks in Parkinson’s Patient
Hand movements induced eyeblinks in a 70-year-old man with Parkinson’s disease, a case study reported for the first time.
Changes in Vitamin D Receptor Gene Tied to Disease Risk, Side Effects
Variations in the gene that encodes for the vitamin D receptor were associated with the risk of developing Parkinson’s…
Peripheral Neuropathy Can Be Evident, Levodopa Link Possible
Damage to certain nerve fibers in the extremities, known as peripheral neuropathy, was evident in some people with Parkinson’s…
Phase 2 Trial of NLY01 in Slowing Disease Progression Fully Enrolled
Enrollment is complete in the Phase 2 study evaluating Neuraly‘s NLY01, an investigational disease-modifying agent designed to slow or…